Tke, what I am having a hard time with, is the dichotomy between how we here view the Denner insertion into Amarin and that the market does not seem to have the same conviction about following his lead. He is of course down on his purchases but I wonder if the overall market has simply been too bearish for his reputation to overcome?
I have seen so many companies with no revenue do so much better than Amarin, pps wise over the years making it hard to understand how Amarin pps struggles considering it is not losing gobs of money, has an FDA approved drug for a major indication and is expanding worldwide. But over those years I have learned that the market values growth and future prospects. Right now Amarin is not giving the market anything as far as hard numbers to look forward to and the market sees US sales declining. Declining is not something the market values.
News 
Market Data 
Discover 
